SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to speculation surrounding its potential inclusion in the S&P 500, sparking bullish sentiment and driving conversations about the potential "index effect" and forced ETF buying. The community is actively discussing strategies around options and covered calls, while also weighing the potential for a "sell the news" reaction post-inclusion. Some are comparing Robinhood to other stocks that were added to the S&P 500.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as traders discuss the potential for inclusion in the S&P 500, though sentiment is mixed. The community debates whether it deserves inclusion as a bitcoin proxy, with some suggesting its fate is tied to bitcoin's price action, while others eye a potential sell-off if it's excluded. Discussions also involve covered call strategies and comparisons to other stocks added to the index.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending due to its impending addition to the S&P 500, driving forced ETF buying and increased liquidity, though some traders are anticipating a short-term pullback following the inclusion. Community discussions revolve around the potential for new all-time highs and the long-term implications of S&P 500 membership, with some skepticism regarding short reports from firms like Muddy Waters.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around upcoming airdrops and staking opportunities. The coin's growing watcher count and bullish sentiment are fueling discussions about potential market cap milestones and ongoing buy contests. Community members express excitement about the project's long-term vision, developments and transparency.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SOFI is trending due to speculation surrounding its potential inclusion in the S&P 500, with community members actively discussing the possibility and implications. Despite some disappointment over recent news, the stock is experiencing a surge in interest following a new partnership with Josh Allen and positive analyst ratings. Bullish investors express optimism for continued growth, while others remain cautious about valuation and potential dilution.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending despite closing a $300 million investment from Uber, with the stock hitting new lows post reverse split. The community is actively discussing the company's financial health, potential for a short squeeze, and whether the reverse split was a strategic move or a sign of deeper issues. Some investors express long-term optimism while others voice concerns about management and the company's ability to compete in the EV market.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase ($COIN) is seeing active discussion driven by its volatile price action and relationship with crypto markets, with community members debating resistance levels and potential for a bounce. Some traders are expressing frustration with the stock's performance relative to Bitcoin and the broader market, while others highlight upcoming catalysts and potential for longer-term growth. The launch of Coinbase's new equity index future, combining top tech stocks with crypto ETFs, is also drawing attention as a strategic move.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue is trending due to reports linking Tylenol use during pregnancy to autism, sparking debate among investors and drawing attention to potential legal ramifications. While some dismiss the claims as overblown and see a buying opportunity, others express concern and anticipate further declines. Community discussions also involve the stock's dividend yield and potential recovery.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF ($MSTY) is trending as investors discuss its recent performance, particularly in relation to MicroStrategy ($MSTR) and Bitcoin. Concerns are emerging regarding NAV erosion and the sustainability of dividend payouts, with some community members expressing bearish sentiment. Others remain optimistic, viewing dips as buying opportunities and emphasizing the potential for high yield and long-term gains, especially if $MSTR is included in the S&P 500.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as holders discuss the Solana ($SOL.X) rewards they receive simply for holding the token, fostering a strong sense of community and long-term investment. Despite price fluctuations, community members highlight the consistent rewards and the project's resilience, with some noting recent partnerships and a community-driven approach. The project is presented as a unique opportunity to earn passive income in the crypto space, emphasizing community ownership and innovative technology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results 

CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.

Company News for Sep 3, 2025

Companies In The News Are: SIG, PEP, CYTK, AL.

Retail chatter around Cytokinetics surged late&nbsp;Monday&nbsp;as the company’s shares jumped 34% in Europe after new data from its MAPLE-HCM study were presented at the European Society of Cardiology Congress 2025 in Madrid.Cytokinetics’ shares closed at €39.8 on Monday in Europe, up €10, or 33.6% from the prior session.The company stated that its experimental drug, aficamten, improved exercise capacity in patients with obstructive hypertrophic cardiomyopathy, whereas treatment with the current standard of care, metoprolol, reduced it.The primary results were also published in The New England Journal of Medicine.MAPLE-HCM is a Phase 3 randomized, double-blind, active-comparator trial that enrolled 175 patients, who were assigned one-to-one to receive either aficamten or metoprolol as monotherapy.&nbsp;Cytokinetics said the trial was designed differently from its pivotal SEQUOIA-HCM study, enrolling patients with less severe disease, including those without obstruction at rest and with higher predicted peak oxygen uptake.Fady I. Malik, executive vice president of research and development, said the clinical difference between the two treatments was reinforced by secondary endpoints on symptoms, functional class and left ventricular outflow tract (LVOT) gradients, and that the benefits were seen in a broader patient population than in SEQUOIA-HCM.Cytokinetics also presented additional data from MAPLE-HCM at the ESC Congress, including a pre-specified analysis of aficamten’s effect on cardiac structure and function, published in the Journal of the American College of Cardiology.&nbsp;A late-breaking clinical science presentation on the incidence and impact of atrial fibrillation associated with aficamten was simultaneously published in Heart Rhythm.“The additional data presented at the ESC Congress 2025 continue to strengthen the evidence base supporting the overall safety profile of aficamten, including as has been observed with a real-world dosing strategy,” Malik said.&nbsp;On Stocktwits, retail sentiment for Cytokinetics was ‘extremely bullish’ amid a 150% surge in 24-hour message volume.One user stated that Cytokinetics appeared to be a clear buyout candidate, citing its head-to-head superiority over the standard-of-care metoprolol.<stembedurl>https://stocktwits.com/lebranjames/message/627145099</stembedurl>Another user noted that while Cytokinetics had strong data, it would still require significant funding, partnerships, and guideline updates before its drug could replace beta blockers, although they expected the stock to trade higher next week.&nbsp;<stembedurl>https://stocktwits.com/John62/message/627141611</stembedurl><a href="https://stocktwits.com/symbol/CYTK">Cytokinetics’ stock</a> has declined 25% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cytokinetics’ stock (CYTK) has declined 25% so far in 2025. (Photo credit: Getty Images)

Retail Buzz Soars As Cytokinetics Jumps 34% In Europe On Heart Drug Breakthrough 

The company unveiled Phase 3 MAPLE-HCM results showing aficamten outperformed metoprolol in obstructive hypertrophic cardiomyopathy, with findings published across top medical journals.

Equity

Will Camzyos Strengthen BMY's Cardiovascular Portfolio?

Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.

Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of +16.42% and +1,658.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Beats Q4 Earnings and Revenue Estimates

Techne (TECH) delivered earnings and revenue surprises of +6.00% and +0.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?

Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound?

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 30, 2025 NEW YORK, Jan...

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

CYTK
Cytokinetics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CYTK News

CYTK Cytokinetics Inc